CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED IS OMITTED AND IS NOTED AS FOLLOWS **REDACTED**. AN
UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
LICENSE AND COLLABORATION AGREEMENT
THIS LICENSE AND COLLABORATION AGREEMENT (the “ Agreement ”) is entered into this 26th day of July 2006
(the “ Effective Date ”) by and between Santaris Pharma A/S , a Danish corporation having its principal place of business at
Hørsholm, Denmark (“ Santaris ”), and Enzon Pharmaceuticals, Inc. , a Delaware corporation having its principal place of
business at Bridgewater, New Jersey 08807 (“ Enzon ”). Santaris and Enzon may be referred to herein individually as a “ Party ”
or collectively, as the “ Parties ”.
Enzon is a pharmaceutical company engaged in the discovery, development, marketing, manufacture and distribution of
pharmaceutical products. Santaris is a pharmaceutical company engaged in the discovery, development and manufacture of,
among other molecules, RNA antagonists for the treatment of oncology indications, and has developed RNA antagonists
referred to as SPC2968 and SPC3042. Santaris and Enzon desire to enter into an arrangement pursuant to which (a) Enzon will
obtain rights to develop SPC2968 and SPC3042 for commercialization in the Enzon Territory and provide data for use by Santaris
in the Santaris Territory, and (b) Santaris will design and synthesize RNA antagonists directed against six (6) Targets (as
defined below) selected by Enzon, and each Party will have the right to develop such antagonists and to commercialize such
antagonists pursuant to the terms of this Agreement.
The Parties agree as follows:
1.1 “ Abandoned Target ” shall have the meaning set forth in Section 5.8.
1.2 “ Accepted LNA Compound” shall have the meaning set forth in S